Efficacy and safety of trastuzumab plus different chemotherapy regimens in treatment of the patients with HER-2-positive advanced breast cancer
10.3760/cma.j.issn.0253-3766.2014.05.011
- VernacularTitle:曲妥珠单抗联合不同化疗方案治疗人表皮生子因子受体2阳性晚期乳腺癌的疗效和安全性
- Author:
Jihong GUO
1
;
Binghe XU
;
Fei MA
;
Ying FAN
;
Peng YUAN
;
Jiayu WANG
;
Ruigang CAI
;
Qing LI
;
Pin ZHANG
Author Information
1. 100021,北京协和医学院 中国医学科学院肿瘤医院内科
- Keywords:
Breast neoplasms;
Human epidermal growth factor receptor 2;
Trastuzumab;
Drug therapy;
Treatment outcome
- From:
Chinese Journal of Oncology
2014;(5):372-376
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of trastuzumab plus different chemotherapy regimens in treatment of patients with HER-2-positive advanced breast cancer .Methods 132 patients with advanced HER-2-positive breast cancer were treated with trastuzumab plus different regimens . The clinical characteristics, efficacy and toxicity of the 132 patients were retrospectively analyzed.Results Five patients had complete response ( CR ) , 61 patients had partial response ( PR ) , 39 patients had stable disease (SD), and 27 patients had progressive disease (PD).The objective response rate was 50.0%and the disease control rate was 79.5%.The median progression-free survival was 9.3 months.The median overall survival time was 46.2 months.The 1-, 2-, 5-year survival rates were 98.3%, 81.9% and 40.2%, respectively.Trastuzumab combined with chemotherapy is superior to trastuzumab monotherapy (51.2%vs.33.3%).The number of metastatic sites , efficacy, different previous treatment lines were independent prognostic factors of PFS (P=0.002, P<0.0001 and P<0.0001, respectively).Visceral metastases, pathological grade, and PFS were independent prognostic factors of OS (P=0.041, P=0.001, P=0.025, P<0.001, P<0.0001 and P<0.0001, respectively).Regarding the toxicities, one case discontinued treatment due to the decrease of left ventricular ejection fraction to 47%, two cases had heartbeat tachycardia , 6 cases had palpitation , 17 cases had a fever during first input trastuzumab .No other serious cardiac toxicity was observed .The most common toxicities were chemotherapy-related hematological and non-hematological toxicities .Conclusions Trastuzumab combined with chemotherapy is superior to trastuzumab monotherapy . Patients may get benefits for early use of trastuzumab . Trastuzumab plus chemotherapy is effective and well tolerated in patients with advanced HER-2 positive breast cancer .No heart failure occurred in this series of patients , and cardiac safety seems better than that in Caucasians because of younger age at the onset in Chinese advanced breast cancer patients .
